安立生坦联合他达拉非初始联合治疗CTD-PAH:AMBITION试验亚组分析
AMBITION试验的事后亚组分析纳入187例CTD-PAH患者(其中118例为SSc-PAH),比较安立生坦联合他达拉非初始联合治疗与单药治疗。结果显示初始联合治疗较单药治疗汇合组显著降低临床失败风险:CTD-PAH亚组HR 0.43(95%CI 0.24-0.77),SSc-PAH亚组HR 0.44(95%CI 0.22-0.89)。
要点
- CTD-PAH患者初始联合治疗较单药汇合降低临床失败风险(HR 0.43)。
- SSc-PAH亚组同样获益,临床失败风险HR 0.44。
- 外周水肿为最常见不良事件,联合治疗组报告更频繁。
核心结论
- CTD-PAH和SSc-PAH患者可从安立生坦联合他达拉非初始联合治疗中获益。
研究设计与样本
- AMBITION试验的事后亚组分析,该试验为事件驱动、双盲设计,纳入WHO功能分级II/III级PAH初治患者。
- 初治患者按2:1:1随机分配至每日一次安立生坦联合他达拉非初始联合治疗组、安立生坦单药组或他达拉非单药组。
- 主要分析集N=500,其中CTD-PAH患者187例,SSc-PAH患者118例。
主要发现
- CTD-PAH亚组中,初始联合治疗较单药汇合组降低临床失败风险,HR 0.43(95%CI 0.24-0.77)。
- SSc-PAH亚组中,初始联合治疗较单药汇合组降低临床失败风险,HR 0.44(95%CI 0.22-0.89)。
- 最常见不良事件为外周水肿,在两个PAH亚组中初始联合治疗组报告频率均高于单药组。
- 联合治疗与单药治疗之间不良事件相对频率在各亚组间相似。
关键数值与推荐
- 主要终点为至首次临床失败事件的时间,临床失败定义为死亡、因PAH恶化住院、疾病进展或长期临床反应不满意中任一事件首次发生。
临床怎么用
- 对于CTD-PAH及SSc-PAH的WHO功能分级II/III级初治患者,可考虑安立生坦联合他达拉非初始联合治疗以降低临床失败风险。
- 治疗期间需关注外周水肿等不良事件,联合治疗组报告频率更高。
局限性
- 本研究为AMBITION试验的事后亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an attenuated response compared with idiopathic PAH in most trials. Thus, there is uncertainty regarding the benefit of PAH-targeted therapy in some forms of CTD-PAH. OBJECTIVE: To explore the safety and efficacy of initial combination therapy with ambrisentan and tadalafil versus ambrisentan or tadalafil monotherapy in patients with CTD-PAH and SSc-PAH enrolled in the AMBITION trial. METHODS: This was a post hoc analysis of patients with CTD-PAH and SSc-PAH from AMBITION, an event-driven, double-blind trial in patients with WHO functional class II/III PAH. Treatment-naive patients were randomised 2:1:1 to once-daily initial combination therapy with ambrisentan plus tadalafil or monotherapy with ambrisentan or tadalafil, respectively. The primary endpoint was time to the first clinical failure event (first occurrence of death, hospitalisation for worsening PAH, disease progression or unsatisfactory long-term clinical response). RESULTS: In the primary analysis set (N=500), 187 patients had CTD-PAH, of whom 118 had SSc-PAH. Initial combination therapy reduced the risk of clinical failure versus pooled monotherapy in each subgroup: CTD-PAH (HR 0.43 (95% CI 0.24 to 0.77)) and SSc-PAH (0.44 (0.22 to 0.89)). The most common AE was peripheral oedema, which was reported more frequently with initial combination therapy than monotherapy in the two PAH subgroups. The relative frequency of adverse events between those on combination therapy versus monotherapy was similar across subgroups. CONCLUSIONS: This post hoc subgroup analysis provides evidence that CTD-PAH and SSc-PAH patients benefit from initial ambrisentan and tadalafil combination therapy. TRIAL REGISTRATION NUMBER: NCT01178073, post results.
引用
- Coghlan JG, Galiè N, Barberà JA, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2016. PMID: 28039187. doi:10.1136/annrheumdis-2016-210236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。